Sangamo’s cell therapy receives EC orphan medicinal product designation
TX200 is developed to reduce the transplant rejection risk in HLA-A2 mismatched kidney transplant from a living donor.
Hasini Devarasetti
Latest articles
All Articles
Ipsen to buy biopharmaceutical company Epizyme for $247m
The acquisition is focused on Tazverik (tazemetostat), a first-in-class chemotherapy-free EZH2a inhibitor.
Biogen, Alectos collaborate to develop Parkinson’s disease treatment
The deal will combine Alectos’ therapeutics expertise with Biogen’s development capabilities in movement disorders.
Emergent sends notice to Janssen over Covid-19 vaccine contract
The notice says that Janssen intends to not purchase the minimum quantity of product mentioned in the initial agreement.
Pfizer plans $120m investment for Covid-19 oral drug manufacturing in US
The latest expansion will create more than 250 new high-skilled manufacturing jobs at the company’s Kalamazoo facility.
China’s NMPA accepts Innovent and IASO Bio’s multiple myeloma therapy NDA
The acceptance of NDA is based on data obtained from an open-label, multi-centre, single-arm Phase I/II study.
EMA grants orphan medicinal product designation to Applied’s AT-007
AT-007 also received Fast Track designation from the US FDA to treat Galactosemia.
Biological E’s Covid-19 vaccine Corbevax gets DCGI approval as booster dose
Corbevax will be given after six months of the first two doses of either Covaxin or Covishield vaccines.
Aeterna Zentaris and JMU expand research for Covid-19 and chlamydia shots
JMU will use human 3D intestinal tissue models to study the infection biology of Salmonella strains.